CDK1 and acute myeloid leukemia: In line with AML cell line results, our results support a model where STK3 inhibition leads to aberrant activation of CDK1/cyclin B1 in a subset of AML cell lines and primary patient samples, which triggers cell death specifically in these cells (Figure 7).